ContributorsPublishersAdvertisers

Durvalumab Plus Chemotherapy Improves Survival in Advanced Biliary Tract Cancer

onclive.com
 2022-01-18

Treatment with the PD-L1 inhibitor durvalumab in combination with gemcitabine and cisplatin resulted in significantly improved overall survival vs placebo plus chemotherapy in patients with advanced biliary tract cancer. Treatment with the PD-L1 inhibitor durvalumab (Imfinzi) in combination with gemcitabine and cisplatin resulted in significantly improved overall survival (OS)...

www.onclive.com

Comments / 0

Comments / 0